STRATA Skin Sciences, Inc. · OTC:SSKN

STRATA Skin Sciences — Mela Sciences — Needham Growth Conference 2013

35 slides from STRATA Skin Sciences's conference presentation, Jan 17, 2013

  1. Slide 1: MelaFind - Needham Growth Conference

    MelaFind® Optics by Carl Zeiss Needham Growth Conference MELA Sciences, Inc. January 16, 2013 ©MELA Sciences 2012

  2. Slide 2: Forward Looking Statements

    Forward Looking Statements This presentation includes “forward-looking statements” within the meaning of the Securities Litigation Reform Act of 1995. These statements include but are not limited to our plans, objectives, expectations and intentions and other statements that contain words such as “e

  3. Slide 3: Development History

    Development History 1995 First application of computer vision technology to melanoma 1998 Initiation of development of MelaFind 2004 Protocol Agreement with FDA 2005 Initial Public Offering 2006 Establish commercial-grade manufacturing methods & supplier 2007-08 Execute pivotal trial 2009 PMA (Pre-M

  4. Slide 4: Launch Progress Since March 2012

    Launch Progress Since March 2012 13 Cities in Germany 25 States in US ©MELA Sciences 2012 MelaFind® Optics by Carl Zeiss

  5. Slide 5: Commercial Strategy 1st months

    Commercial Strategy 1st 12 months • Placement of MelaFind system ~$10,000 • ~$50/exam • Self-pay initially • Dermatologists • US – goal of 200 signed contracts • Germany – goal of 75 signed contracts ©MELA Sciences 2012 MelaFind® Optics by Carl Zeiss

  6. Slide 6: Revenue Contributions YTD

    Revenue Contributions 9 Mo’s YTD Sales COGS Gross Profit R & D G & A Other Total ELEMENTS OF REVENUE Initial Placement Fee: $2K of $10,000 ( $8K to “deferred revenue”) Placement Fee balance recognized @ $333/month for 24 months Card Sales - $2,500 per box of 50 (1 per patient) ($ Germany – alternate

  7. Slide 7: 43.7M Medical & Cosmetic Procedures in the US per Year

    43.7 M Medical & Cosmetic Procedures in the US per Year 37 Million Patients for Medical Visits1 13% 25% 20% 7% 2% 3% 3% 6% 3% 4% 11% Acne Skin Rash Skin Lesions, Moles & Other Skin Growths Warts Discoloration or Pigmentation Other Skin Symptoms Hair and scalp issues Skin Irritations Cancer, Skin & S

  8. Slide 8: MelaFind increases dermatologist compensation

    MelaFind increases dermatologist compensation, without taking time away from the patient MelaFind can add >$96,000/per year to a dermatologist’s compensation if used once an hour and charging $100 per session Average Income: Dermatologist by Geographical Area Source: Medscape Dermatology Compensatio

  9. Slide 9: 2012 Accomplishments

    2012 Accomplishments Launched MelaFind (March) Product upgrades Developed infrastructure for national business Many examples of clinical benefit of MelaFind Melanomas detected Unnecessary biopsies averted Ended year with over 100 signed user agreements Cleveland Clinic Top 10 Innovations for 2013; o

  10. Slide 10: 2013 Goals

    2013 Goals Drive toward goal of 275 signed use agreements by March 31, 2013 Expedite MelaFind practice integration & increased usage: 1. Practice commitment at time of placement 2. Peer to peer medical communications 3. Patient communications 4. Enhanced client services Reduce manufacturing costs si

  11. Slide 11: 2013 Key Tactics

    2013 Key Tactics Dermatology meetings 1. Winter Clinical 2. Orlando Derm Aesthetic & Clinical 1Q 2013 3. Winter Skin 4. Annual AAD meeting Agency (Rpr) efforts 1. Consumer Media & Skin Cancer Detection campaigns 2. Health & Beauty Magazine PR 3. Melanoma Monday campaign 4. Targeted patient mobilizat

  12. Slide 12: Rpr Client & Industry Experience

    Rpr Client & Industry Experience MELA Sciences 2012 MelaFind Optics by Carl Zeiss

  13. Slide 13: Usage

    Usage Rolling-out tactics to increase awareness of melanoma and MelaFind… increasing usage Do you have any moles on your body that look like these? Melanoma is the deadliest form of skin cancer, responsible for 75% of all skin cancer fatalities.1 But when treated early, melanoma is often curable.2 M

  14. Slide 14: MelaFind Advertisements by dermatologists

    MelaFind Advertisements by dermatologists MELA Sciences 2012 MelaFind Optics by Carl Zeiss

  15. Slide 15: MelaFind Advertisements by MELA

    MelaFind Advertisements by MELA IF YOU HAVE SKIN, YOU’RE AT RISK FOR MELANOMA.

  16. Slide 16: MelaFind Chosen as Top Medical Innovation by Cleveland Clinic

    MelaFind Chosen as One of Top 10 Medical Innovations for 2013 by Cleveland Clinic Criteria for Inclusion are Significant Clinical Impact, High Probability of Commercial Success, and Significant Human Interest Press Release: MELA Sciences, Inc. – Mon, Nov 5, 2012 7:00 AM EST NEW YORK, Nov. 5, 2012 (G

  17. Slide 17: MelaFind Presence - 2013 Conference Schedule US

    MelaFind ® Presence 2013 Conference Schedule – US Orlando Dermatology Aesthetic & Clinical Conf. – Jan. (Orlando, FL) Winter Clinical Dermatology Meeting – Jan. (Koloa, HI) Winter Skin Seminar – Jan. (UT) Annual American Academy of Dermatology Meeting – Mar. (Miami, FL) Atlantic Dermatological Confe

  18. Slide 18: MelaFind Presence - Germany Conferences

    MelaFind® Presence Upcoming Dermatology Conferences – Germany Dermatologische Praxis – Mar. (Frankenthal, Germany) 47th DDG-Session – May (Tagung, Germany) European PostASCO Meeting – TBD (Germany) Practical Dermatology & Venerology Conference (FOBI) – TBD (Germany) 8th World Congress of Melanoma –

  19. Slide 19: Why Melanoma?

    Why Melanoma? Melanoma kills 1 US citizen per hour 80% of all skin cancer deaths 50% increase in mortality since 1973 Fastest growing cancer 6% per year 50% increase in women 15-39 Most common cancer in women 25-29 #1 cancer killer in women 30-35 Affects all age groups No cure for late stage disease

  20. Slide 20: Early Detection is the Only Hope for a Cure

    Early Detection is the Only Hope for a Cure ed scars zation ule-out a

  21. Slide 21: How Does MelaFind Work?

    How Does MelaFind Work? Hardware: MelaFind acquires multi?spectral data Uses light in 10 wavelengths from 430 nm (blue) to 950 nm (near infrared) Depth up to 2.5 mm into the skin 20 micron?resolution (sees clusters of 3 melanocytes) Software: Sophisticated proprietary automatic algorithms analyze da

  22. Slide 22: Slide 22

  23. Slide 23: Melanoma in situ - All MelaFind High

    Melanoma in situ Invasive Melanoma, 0.25 mm Invasive Melanoma, 0.30 mm Invasive Melanoma, 0.40 mm ALL MELAFIND “HIGH” Melanoma in situ Invasive Melanoma, 0.50 mm Melanoma in situ Melanoma in situ Melanoma in situ

  24. Slide 24: —_ vauy Bug meee

    —_ vauy Bug meee vii Jvatunncsativeeb ota da apa A Dass cree eummluaoboan DINOTONVOTOROT nT

  25. Slide 25: Low Grade Dysplastic Nevus - All MelaFind Low

    Low Grade Dysplastic Nevus Low Grade Dysplastic Nevus Seborrheic Keratosis Seborrheic Keratosis ALL MELAFIND “LOW” Low Grade Dysplastic Nevus Low Grade Dysplastic Nevus Low Grade Dysplastic Nevus Low Grade Dysplastic Nevus Compound Nevus

  26. Slide 26: Standard images: invasive melanoma vs dysplastic nevus

    Example 1 Figure 6. Standard images Invasive melanoma (2P) Low-grade dysplastic nevus (3J) Dermoscopic Clinical close-up Clinical overview Melanoma has eccentric and intense asymmetry at all depths versus benign lesion. Figure 8. Asymmetry images [wavelength (mm) and penetration (mm) and penetractio

  27. Slide 27: Asymmetry images by wavelength and depth

    Example 2 (2.5 mm) 430 nm (0.4mm) 460 nm (0.7 mm) 510 nm (0.9 mm) 600 nm (1.7 mm) 660 nm (1.7 mm) 780 nm (2.0 mm) 880 nm (2.2 mn) 950 nm (2.5 mm) © MELA Sciences 2012 Invasive Melanoma Low Grade Dysplastic Nevus Invasive Melanoma Low Grade Dysplastic Nevus Invasive Melanoma Low Grade Dysplastic Nevu

  28. Slide 28: Summary of MelaFind Performance

    Summary of MelaFind Performance Pivotal Trial (n = 1612 lesions in primary endpoint) Biopsy 98.3% (112/114*) 95% LCB = 95.1% Sensitivity Average: Biopsy MelaFind: 9.5% p = 0.02 Specificity Dermatologists: 3.7% Adjunctive Reader Study (110 Dermatologists) Biopsy MelaFind: 97% (63/65) p < 0.0001 Sensi

  29. Slide 29: Arch Dermatol. February 20, 2012

    Arch Dermotol. February 20, 2012 Dr. Darrell Rigel, New York University 179 attending dermatologists participated 24 pigmented skin lesions (5 melanomas, 19 non-melanomas) Biopsy decision before and after provision of MelaFind result recorded Before After Metric MelaFind MelaFind Comments Sensitivit

  30. Slide 30: Published in Premier Academic Journals

    Published in Premier Academic Journals STUDY Online First The Performance of MetaFind A Prospective Multicenter Study Gary Monheit, MD; Armand B. Cognetta, MD; Laura Ferris, MD, Mary Martini, MD; James M. Grichnik, MD, PhD; Martin Mihm, Roy King, MD; Alicia Toledano, ScD; Nikolai Kabelev, BCSc; Obje

  31. Slide 31: German Reader Study

    German Reader Study (n = 202 dermatologists) Percent of Number of melanomas Sensitivity Specificity dermatologists Specificity detected by 90% of Sensitivity > 90% dermatologists Arm 1 – 101 dermatologists 70.5% 54% 3 23% 9.2% with clinical information only Arm 2 – 101 dermatologists with clinical 7

  32. Slide 32: Clinically Atypical Pigmented Skin Lesions

    Clinically Atypical Pigmented Skin Lesions Pigmented skin lesions having one or more clinical or historical characteristics of melanoma: 14. ABCD: Asymmetry, Border Irregularity, Color Variegation, Diameter > 6 mm1 5. E – Evolving2,3 6. P – Patient’s Concern4,5,6 7. R – Regression7 8. U – Ugly Duckl

  33. Slide 33: Patient In the Clinic

    Patient In the Clinic The examining dermatologists’ expertise allows him/her to easily differentiate obviously benign lesions (i.e. freckles)… from an obviously malignant lesion… However, atypical lesions are difficult to differentiate… 33 MelaFind optics by Carl Zeiss MELA Sciences 2012

  34. Slide 34: Summary

    Summary Summary Market for melanoma detection is large and growing Significant unmet medical need MelaFind® is a breakthrough product for early detection Largest positive prospective trial ever performed in melanoma detection Launched March 7, 2012 – US & Germany Goal: by March 31, 2013 – 200 system

  35. Slide 35: Evolution of MelaFind

    Evolution of MelaFind MelaFind optics by Carl Zeiss MELA Sciences 2012

Mela Sciences — Needham Growth Conference 2013 on 6ix